Adelaide
Clinical Trials
GPN Vaccines is developing vaccines to protect adults and children from the world’s most deadly pathogens.
Our lead product, Gamma-PN, has been shown to be safe, well-tolerated, and able to induce antibodies to all pneumococcal strains in 120 healthy volunteers aged 50-69. Future clinical trials will continue to assess the safety and effectiveness of Gamma-PN in children and the elderly, who are most susceptible to potentially life-threatening pneumococcal infections.
Clinical Trials
GPNV-008
About GPNV-008
GPNV-008 is a Phase 1b, open-label study to collect serum following vaccination with Gamma-PN in healthy men and women.
Are you eligible?
- Generally in a good health?
- Aged between 25-69?
- Weigh at least 70kg?
- Living in Adelaide?
*There are many criteria to join a clinical trial and we recommend discussing your eligibility with your GP.
Interested?
Expression of Interest can be sent to clinicaltrials@gpnvaccines.com
GPNV-006 (STUDY COMPLETED)
About GPNV-006
GPNV-006 is a Phase 1, randomised, active-controlled, blinded, dose-ranging study of the safety, tolerability, and immunogenicity of Gamma-PN3 in participants 70 and older.